---
title: "Medtronic Announces Positive EMBOLISE Trial Results for Onyx LES in Chronic Subdural Hematoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275018957.md"
datetime: "2026-02-05T18:55:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275018957.md)
  - [en](https://longbridge.com/en/news/275018957.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275018957.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275018957.md) | [繁體中文](https://longbridge.com/zh-HK/news/275018957.md)


# Medtronic Announces Positive EMBOLISE Trial Results for Onyx LES in Chronic Subdural Hematoma

Medtronic plc has announced additional data from the EMBOLISE clinical trial, a multicenter, prospective, and randomized study in the United States evaluating the OnyxTM Liquid Embolic System (LES) for middle meningeal artery (MMA) embolization in patients with symptomatic subacute or chronic subdural hematoma (cSDH). The trial compared MMA embolization using Onyx LES to observation only. Results showed that the Test arm (Onyx MMA embolization) met the pre-specified 90-day primary effectiveness endpoint and demonstrated a positive trend in 180-day imaging for hematoma improvement compared to the control arm. Previous findings from the Surgery Cohort, published in the New England Journal of Medicine in November 2024, indicated a 63% reduction in treatment with surgery plus MMA embolization compared to surgery alone. The data have been presented at multiple major conferences and published in journals including NEJM, Radiology, and JNIS. Medtronic announced an indication expansion in the U.S. for the Onyx 18 and 34 liquid embolic system as an adjunct to surgery in December 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Medtronic plc (MDT.US)](https://longbridge.com/en/quote/MDT.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [BUZZ-Wall Street bullish on MiniMed after $560 million IPO](https://longbridge.com/en/news/281229113.md)
- [08:15 ETEllipsys Vascular Access System to Return to U.S. Market in 2026](https://longbridge.com/en/news/281522014.md)
- [BUZZ-Tempus AI rises after study shows AI-driven alerts improve heart valve treatment](https://longbridge.com/en/news/281390073.md)
- [Perimeter Posts Record 2025 Revenue and Wins FDA Approval for AI Breast Imaging Device](https://longbridge.com/en/news/281274047.md)
- [Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD](https://longbridge.com/en/news/281179756.md)